Akeem A Yusuf1, Benjamin L Howell2, Christopher A Powers3, Wendy L St Peter4. 1. Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN; University of Minnesota, College of Pharmacy, Minneapolis, MN. 2. Center for Medicare and Medicaid Innovation, Centers for Medicare & Medicaid Services, Baltimore, MD. 3. Center for Strategic Planning, Centers for Medicare & Medicaid Services, Baltimore, MD. 4. Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN; University of Minnesota, College of Pharmacy, Minneapolis, MN. Electronic address: wstpeter@cdrg.org.
Abstract
BACKGROUND: Information is limited regarding utilization patterns and costs for chronic kidney disease-mineral and bone disorder (CKD-MBD) medications in Medicare Part D-enrolled dialysis patients. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Annual cohorts of dialysis patients, 2007-2010. PREDICTORS: Cohort year, low-income subsidy status, and dialysis provider. OUTCOMES: Utilization and costs of prescription phosphate binders, oral and intravenous vitamin D analogues, and cinacalcet. MEASUREMENTS: Using logistic regression, we calculated adjusted odds of medication use for low-income subsidy versus non-low-income subsidy patients and for patients from various dialysis organizations, and we report per-member-per-month and average out-of-pocket costs. RESULTS: Phosphate binders (∼83%) and intravenous vitamin D (77.5%-79.3%) were the most commonly used CKD-MBD medications in 2007 through 2010. The adjusted odds of prescription phosphate-binder, intravenous vitamin D, and cinacalcet use were significantly higher for low-income subsidy than for non-low-income subsidy patients. Total Part D versus CKD-MBD Part D medication costs increased 22% versus 36% from 2007 to 2010. For Part D-enrolled dialysis patients, CKD-MBD medications represented ∼50% of overall net Part D costs in 2010. LIMITATIONS: Inability to describe utilization and costs of calcium carbonate, an over-the-counter agent not covered under Medicare Part D; inability to reliably identify prescriptions filled through a non-Part D reimbursement or payment mechanism; findings may not apply to dialysis patients without Medicare Part D benefits or with Medicare Advantage plans, or to pediatric dialysis patients; could identify only prescription drugs dispensed in the outpatient setting; inability to adjust for MBD laboratory values. CONCLUSIONS: Part D net costs for CKD-MBD medications increased at a faster rate than costs for all Part D medications in dialysis patients despite relatively stable use within medication classes. In a bundled environment, there may be incentives to shift to generic phosphate binders and reduce cinacalcet use.
BACKGROUND: Information is limited regarding utilization patterns and costs for chronic kidney disease-mineral and bone disorder (CKD-MBD) medications in Medicare Part D-enrolled dialysis patients. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Annual cohorts of dialysis patients, 2007-2010. PREDICTORS: Cohort year, low-income subsidy status, and dialysis provider. OUTCOMES: Utilization and costs of prescription phosphate binders, oral and intravenous vitamin D analogues, and cinacalcet. MEASUREMENTS: Using logistic regression, we calculated adjusted odds of medication use for low-income subsidy versus non-low-income subsidy patients and for patients from various dialysis organizations, and we report per-member-per-month and average out-of-pocket costs. RESULTS:Phosphate binders (∼83%) and intravenous vitamin D (77.5%-79.3%) were the most commonly used CKD-MBD medications in 2007 through 2010. The adjusted odds of prescription phosphate-binder, intravenous vitamin D, and cinacalcet use were significantly higher for low-income subsidy than for non-low-income subsidy patients. Total Part D versus CKD-MBD Part D medication costs increased 22% versus 36% from 2007 to 2010. For Part D-enrolled dialysis patients, CKD-MBD medications represented ∼50% of overall net Part D costs in 2010. LIMITATIONS: Inability to describe utilization and costs of calcium carbonate, an over-the-counter agent not covered under Medicare Part D; inability to reliably identify prescriptions filled through a non-Part D reimbursement or payment mechanism; findings may not apply to dialysis patients without Medicare Part D benefits or with Medicare Advantage plans, or to pediatric dialysis patients; could identify only prescription drugs dispensed in the outpatient setting; inability to adjust for MBD laboratory values. CONCLUSIONS: Part D net costs for CKD-MBD medications increased at a faster rate than costs for all Part D medications in dialysis patients despite relatively stable use within medication classes. In a bundled environment, there may be incentives to shift to generic phosphate binders and reduce cinacalcet use.
Keywords:
Chronic kidney disease (CKD); Medicare Part D; calcimimetics; dialysis; medication costs; mineral and bone disorder; phosphate binders; vitamin D analogues
Authors: Benjamin L Howell; Christopher A Powers; Eric D Weinhandl; Wendy L St Peter; Diane L Frankenfield Journal: J Am Soc Nephrol Date: 2012-03-08 Impact factor: 10.121
Authors: Diane L Frankenfield; Eric D Weinhandl; Christopher A Powers; Benjamin L Howell; Charles A Herzog; Wendy L St Peter Journal: Am J Kidney Dis Date: 2011-12-28 Impact factor: 8.860
Authors: Naomi C Sacks; James F Burgess; Howard J Cabral; Steven D Pizer; Marie E McDonnell Journal: J Gen Intern Med Date: 2013-02-13 Impact factor: 5.128
Authors: Britt B Newsome; Ryan D Kilpatrick; Jiannong Liu; David Zaun; Craig A Solid; Kimberly Nieman; Wendy L St Peter Journal: Am J Nephrol Date: 2013-07-30 Impact factor: 3.754
Authors: Kamyar Kalantar-Zadeh; Jessica E Miller; Csaba P Kovesdy; Rajnish Mehrotra; Lilia R Lukowsky; Elani Streja; Joni Ricks; Jennie Jing; Allen R Nissenson; Sander Greenland; Keith C Norris Journal: J Bone Miner Res Date: 2010-07-07 Impact factor: 6.741
Authors: Julie H Ishida; Charles E McCulloch; Michael A Steinman; Barbara A Grimes; Kirsten L Johansen Journal: J Am Soc Nephrol Date: 2018-06-05 Impact factor: 10.121
Authors: Julie H Ishida; Charles E McCulloch; Michael A Steinman; Barbara A Grimes; Kirsten L Johansen Journal: Clin J Am Soc Nephrol Date: 2018-04-19 Impact factor: 8.237
Authors: Sun Moon Kim; Jin Long; Maria E Montez-Rath; Mary B Leonard; Jeffrey A Norton; Glenn M Chertow Journal: Clin J Am Soc Nephrol Date: 2016-06-06 Impact factor: 8.237